
I-Mab IMAB
Quarterly report 2025-Q4
added 04-25-2026
I-Mab Depreciation & Amortization 2011-2026 | IMAB
Annual Depreciation & Amortization I-Mab
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 23.9 M | 25.3 M | 13.8 M | 12.7 M | 9.8 M | 6.7 M | 1.6 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 25.3 M | 1.6 M | 13.4 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Happiness Biotech Group Limited
HAPP
|
380 K | - | 1.35 % | $ 17.8 M | ||
|
Compugen Ltd.
CGEN
|
475 K | $ 2.22 | 1.37 % | $ 207 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
1.3 M | $ 1.58 | 7.14 % | $ 185 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
2.1 M | - | - | $ 2.18 B | ||
|
AstraZeneca PLC
AZN
|
5.73 B | - | - | $ 96.9 B | ||
|
Athira Pharma
ATHA
|
972 K | - | - | $ 269 M | ||
|
Galera Therapeutics
GRTX
|
20 K | - | -32.59 % | $ 7.61 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | ||
|
Berkeley Lights
BLI
|
9 M | - | -7.31 % | $ 87 M | ||
|
Celldex Therapeutics
CLDX
|
3.38 M | - | - | $ 1.99 B | ||
|
Generation Bio Co.
GBIO
|
4.93 M | - | - | $ 344 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
5 K | - | -4.36 % | $ 27 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
1.74 M | - | - | $ 384 M | ||
|
Gracell Biotechnologies
GRCL
|
58.8 M | - | - | $ 3.37 B | ||
|
Anika Therapeutics
ANIK
|
5.37 M | $ 14.79 | 2.64 % | $ 212 M | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
24 K | - | - | $ 5.2 M | ||
|
CRISPR Therapeutics AG
CRSP
|
19.5 M | $ 56.95 | 9.35 % | $ 5.12 B | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
7.72 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 21.95 | 2.81 % | $ 2.79 B | ||
|
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K |